ASCO GU 2023: Survival Benefits Sustained With Nivolumab Plus Cabozantinib for First-Line Treatment of Advanced Kidney Cancer
At median 44 months of follow-up, risk for death reduced by 30 percent versus sunitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.